Do you know the new treatment that shows significant improvement in metastasis-free survival and time to symptomatic progression among men with non-metastatic castration-resistant prostate cancer?

News

Chemo-hormonal therapy with docetaxel and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer may improve quality of life compared with androgen deprivation therapy alone.
Findings of a recent study suggest that prostate cancer mortality remains identical among men, regardless of whether or not they underwent single prostate-specific antigen screening.
A recent study compared the clinical outcomes of postoperative adjuvant radiotherapy versus early-salvage radiotherapy administered to patients with stage pT3 prostate cancer or those with positive margins.
A new polygenic score can be used to predict an individual man's age of onset of aggressive prostate cancer - and thereby guide screening efforts.

Research in Review

Luminal and basal subtyping of prostate cancer may provide a clinical tool for predicting which patients will benefit from androgen deprivation therapy (ADT) after prostatectomy, according to a report published in JAMA Oncology (published online May 11, 2017; doi:10.1001/jamaoncol.2017.0751).

-----

Related Content

Read More

A 4-week precision radiotherapy regimen is as effective and safe as the standard 8-week regimen for treating localized prostate cancer, according to research published in the Journal of Clinical Oncology (published online March 15, 2017; doi:10.1200/JCO.2016.71.7397).

Read More

High-dose-rate brachytherapy administered in a single treatment may be a safe and effective alternative for patients with non-metastatic prostate cancer, according to a new study.

-----

Related Content

Read More

Taking one-fourth the recommended dose of a standard drug with a low-fat meal is as effective as taking the recommended dose on an empty stomach for patients with castration-resistant prostate cancer, according to research published in the Journal of Clinical Oncology (2017;35[suppl 6S]:abstract 176).

Read More

Subscribe to Prostate Cancer